BPC August 27 update

​Prothena PRTA +26% on ownership stake by EcoR1 Capital; Sophiris SPHS offering -15%

Price and Volume Movers

Prothena Corporation plc (NASDAQ:PRTA) shares closed up 26% to $8.93, following the filing of a Schedule 13D by EcoR1 Capital on Monday, where it reported a $23.6% ownership stake of the company.

Sophiris Bio Inc. (Nasdaq: SPHS) announced a registered direct offering with one institutional investor for the sale of 5,333,334 shares (or pre-funded warrants to purchase common shares) for an effective price of $0.75 per share, for gross proceeds of approximately $4m. Shares closed down 15% to $0.81.

Mallinckrodt Pharmaceuticals (NYSE: MNK) shares closed down 16% to $3.56 on news that the U.S. Court of Appeals for the Federal Circuit upheld a Federal District Court’s decision rejecting Mallinckrodt’s patent infringement lawsuit against Praxair, Inc.’s nitric oxide drug product delivery system.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume

ADVANCERS:

Plus Therapeutics, Inc. (PSTV): $14.95; +44%.

Cidara Therapeutics, Inc. (CDTX): $1.50; +11%.

Avadel Pharmaceuticals plc (AVDL): $2.45; +9%.

Diffusion Pharmaceuticals Inc. (DFFN): $2.24; +9%.

OncoSec Medical Incorporated (ONCS): $2.04; +8%.

DECLINERS:

Liquidia Technologies Inc.( LQDA): $4.55; -18%.

Endo International plc (ENDP): $2.55; -12%.

Celldex Therapeutics, Inc. (CLDX): $2.07; -11%.

Odonate Therapeutics, Inc. (ODT): $30.32; -11%.

Cerecor Inc. (CERC): $2.99; -10%.


Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ARVN – Arvinas Inc.
ARV-471
ER+ positive / HER2- negative breast cancer

Phase 1 Phase 1 trial initiation announced August 27, 2019 with initial data due 2020.
$856.3 million

DMPI – DelMar Pharmaceuticals Inc.
VAL-083
MGMT-unmethylated newly diagnosed Glioblastoma Multiforme (GBM)

Phase 2 Phase 2 enrolment to be completed 4Q 2020. Potential update due at the Society of Neuro-Oncology meeting November 20-24, 2019.
$6.9 million

DMPI – DelMar Pharmaceuticals Inc.
VAL-083
MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

Phase 2 Phase 2 enrolment to be completed 4Q 2020. Potential update due at the Society of Neuro-Oncology meeting November 20-24, 2019.
$6.9 million

RGNX – REGENXBIO Inc.
RGX-314
Wet age-related macular degeneration (wet AMD)

Phase 1/2 Phase 1/2a data due at AAO October 11, 2019, 4:18 p.m. PT. Phase 2b trial to be initiated late 2019.
$1.5 billion